GRAL vs CDNA

Head-to-Head Stock Analysis & Investment Rating

Last Updated: Jul 28, 2026

GRAL

59.6
AI Score
VS
GRAL Wins

CDNA

50.6
AI Score

Investment Advisor Scores

GRAL

60score
Recommendation
HOLD

CDNA

51score
Recommendation
HOLD

AI Analyst Insights

Detailed Metrics Comparison

Metric GRAL CDNA Winner
Forward P/E 0 94.3396 Tie
PEG Ratio 0 -0.12 Tie
Revenue Growth 28.1% 39.0% CDNA
Earnings Growth 0.0% 0.0% Tie
Tradestie Score 59.6/100 50.6/100 GRAL
Profit Margin -253.2% -2.0% CDNA
Beta 1.00 1.00 Tie
AI Recommendation HOLD HOLD Tie

Relative Price Performance (Last 90 Days)

GRAL 1M: +0.7% · 3M: +25.8% CDNA 1M: +49.4% · 3M: +110.0%

Current Technical Phase

GRAL

Markup
Hold / add on dips

Price above SMA50, rising 50-day trend (8.3% over 20 days), RSI 51

RSI (14): 50.7 · Price: $68.56

CDNA

Markup
Hold / add on dips

Price above SMA50, rising 50-day trend (23.4% over 20 days), RSI 77

RSI (14): 77.4 · Price: $43.71

Fundamentals Snapshot

Metric GRAL CDNA
Market Cap
Forward P/E -7.1 38.5
Trailing P/E
Revenue (TTM)
Revenue Growth 0.3% 0.4%
Gross Margin 0.5% 0.7%
Operating Margin -3.3% 0.0%
EPS -11.55 -0.17
Dividend Yield

Frequently Asked Questions

Based on our detailed analysis, GRAL is currently the stronger investment candidate based on our comprehensive scoring model.

We analyze revenue and earnings growth rates in the "Growth" section above. Generally, the company with higher year-over-year revenue and EPS growth is fostering better expansion. Check the table above for the specific growth percentages.

Valuation is determined by metrics like the P/E Ratio and PEG Ratio. A lower P/E typically suggests a stock is cheaper relative to its earnings. Refer to the "Valuation" section in our comparison table to see which stock currently trades at a more attractive multiple.